CBM-C30.1 is under clinical development by AbelZeta and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase II drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBM-C30.1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBM-C30.1 is under development for the treatment of relapsed and refractory CD30 positive Hodgkin's and Non-Hodgkin's lymphomas. The therapy is administered as infusion. CBM-C30.1 acts by targeting CD30 antigen. The cell therapy constitutes chimeric antigen receptor T-cell (CART) cells.
AbelZeta, formerly Cellular Biomedicine Group Inc, is a clinical-stage biopharmaceutical firm that develops biomedicine, and immunotherapy products for cancer and stem cell therapies to address patient-specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases. It offers treatment protocol services such as orthopedic diseases including osteoarthritis and tissue damage; and other indications. AbelZeta utilizes proprietary cell-based technologies to produce raw materials, manufacture cells, and conduct cell banking and distribution. The firm has operations in Hong Kong, China and the US. AbelZeta is headquartered in Cupertino, California, the US.
For a complete picture of CBM-C30.1’s drug-specific PTSR and LoA scores, buy the report here.